1-alpha antibody shows anti-interleukin new promise in the treatment of patients with advanced colorectal cancer -
A novel anti-interleukin-1 alpha antibody showed an impact significant about the symptoms, and a high level of safety and tolerability in patients with advanced colorectal cancer, according to III data presented at the European Society for the 18th World Congress of medical oncology gastrointestinal cancer Barcelona, Spain phase.
Xilonix is the first monoclonal antibody immunotherapy to specifically target and neutralize interleukin-1 alpha (IL-1α), one of the most potent inflammatory substances produced by the cells of the body or a tumor.
"IL-1α in tumors promotes angiogenesis, helping to provide crucial blood supply to the tumor growth, and it can also send the metabolism of the body out of control, the causing it to burn muscle and lose weight, "said lead investigator Dr. Tamas Hickish. At the same time, the IL-1alpha effects on the brain can cause fatigue, anxiety and anorexia associated with advanced cancer.
The study included 309 patients with metastatic colorectal cancer whose disease has not responded to standard chemotherapy with oxaliplatin and irinotecan, which showed a high degree of symptoms , functional impairment, weight loss or elevated systemic inflammation.
In addition to trialing the new agent, the researchers also introduced new criteria for objective response based on controlling symptoms, which were developed in collaboration with the Scientific Working Group Board of European medicines Agency. These criteria have been applied in conjunction with dual-energy x-ray absorptiometry and EORTC-QLQC30 to assess disease control
Patients were randomized at a 2 :. Report 1 MABp1 with best supportive care or placebo and the same.
Treatment with MABp1 was associated with a relative increase of 76% clinically significant response rate. Patients who experienced a clinical response lived nearly three times longer than those who have not responded (11.5 months against 4.2 months).
The researchers also found that measures to improve the health status correlated with improvement in almost every other car measures reported by police and health laboratory, including with better control of the activity of white blood cells associated with the tumor and reduced systemic inflammation.
There was also a quarter of the less serious side effects in the treatment arm of the study compared with placebo.
"These data suggest Xilonix is very well tolerated, and has the potential to meet the real and urgent need for more effective therapies, less toxic for patients with advanced colorectal cancer," said the Dr Hickish.
"This study also provides the first evidence that health can indeed be used to measure the effectiveness of anti-tumor therapy in advance, refractory colorectal cancer, and clinical responses based on health status can be a predictor of overall survival benefit. "
EmoticonEmoticon